Clinical Scorecard: The Evolving Treatment Landscape for Wet AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Anti-VEGF therapies targeting neovascularization |
| Target Population | Patients with neovascular age-related macular degeneration |
| Care Setting | Ophthalmology clinics and retina subspecialty practices |
Key Highlights
- Extension studies show maintained durability and stable best-corrected visual acuity (BCVA)
- Vabysmo and Eylea HD demonstrate stable central subfield thickness (CST) improvements
- Susvimo shows maintained BCVA and CST reductions in long-term studies
- New treatments include TH-103 with enhanced anti-VEGF activity
- Emerging therapies include TKIs, gene therapy, and zifibancimig
Guideline-Based Recommendations
Diagnosis
- Regular assessment of visual acuity and retinal imaging for diagnosis
Management
- Utilization of anti-VEGF therapies such as Vabysmo, Eylea HD, and Susvimo
Monitoring & Follow-up
- Long-term follow-up with visual acuity and CST measurements
Risks
- Monitor for potential adverse effects associated with anti-VEGF treatments
Patient & Prescribing Data
Patients diagnosed with wet AMD requiring ongoing treatment
Long-term studies indicate sustained efficacy and safety of current therapies
Clinical Best Practices
- Implement regular follow-up schedules for patients on anti-VEGF therapy
- Consider switching to port delivery systems for improved treatment adherence
- Stay updated on emerging therapies and clinical trial data
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
